Using Grey Target Theory for Power Quality Evaluation Based on Power Quality Monitoring Data

Smart grid puts forward higher requirements for power quality.Power quality evaluation can provide a decision-making basis for quality improvement.Based on power quality monitoring data,a grey target method is proposed for power quality evaluation.The grey target is composed of power quality evaluation standard and power quality monitoring data to be evaluated.Combining with the characteristics of each power quality evaluation index,the target center of the whole grey target system is found.Then,the power quality monitoring data to be evaluated and the power quality standard mode are compared and analyzed to construct the power quality grey correlation difference information space.Finally,the target center coefficient and target degree of power quality are calculated to realize the comprehensive evaluation of power quality,and the evaluation grade of power quality monitoring data to be evaluated is obtained.Compared with the evaluation results of the existing literature,the effectiveness of the proposed method is verified,which shows that grey target theory is reasonable in the comprehensive evaluation of power quality.

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma

Objective:This is a prospective,single-arm,phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal squamous cell carcinoma(ESCC).Methods:The regimen encompassed 2-4 cycles of neoadjuvant camrelizumab,nab-paclitaxel,nedaplatin,and apatinib to treatment-naive patients with resectable locally advanced ESCC.The treatment was repeated every 14 days.Initially,six patients were planned to receive two cycles of neoadjuvant therapy as safety assessment,and then 24 patients received four cycles of neoadjuvant therapy,followed by esophagectomy after 4-8 weeks.The primary endpoint was safety.The key secondary endpoints were pathologic complete response(pCR)and major pathologic response(MPR).Results:This study enrolled 30 patients,among whom,five patients received two cycles of neoadjuvant therapy,and one patient missed the second cycle of therapy due to grade 3 elevated alanine transaminase(ALT)level.The remaining 24 patients received four planned cycles of neoadjuvant therapy.Eleven patients(36.7%)devel-oped grade 3 neoadjuvant treatment-related adverse events(TRAEs).No patient developed grade 4 or 5 TRAEs.Neutropenia(23.3%)was the most common grade 3 TRAE.Twenty-nine patients underwent esophagectomy af-ter neoadjuvant therapy.Among them,15 patients(51.7%)achieved MPR,including seven patients with pCR(24.1%).Radiographic analyses established a significant correlation between maximal standardized uptake value(SUV max)reduction and pathologic regression(P=0.00095).Conclusions:Neoadjuvant camrelizumab combined with chemotherapy plus apatinib demonstrated a manageable safety profile for patients with locally advanced ESCC,and an encouraging efficacy was observed in most of the treated patients.A decrease in SUV max of the primary tumor may be a predictor of pathologic response to neoadjuvant camrelizumab combined with chemotherapy plus apatinib in ESCC.

RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m^(6)A modification

Increased rates of ribosome biogenesis have been recognized as hallmarks of many cancers and are associated with poor prognosis.Using a CRISPR synergistic activation mediator(SAM)system library targeting 89 ribosomal proteins(RPs)to screen for the most oncogenic functional RPs in human esophageal squamous cell carcinoma(ESCC),we found that high expression of RPS15 correlates with malignant phenotype and poor prognosis of ESCC.

寡转移或寡进展型食管鳞状细胞癌的概念梳理与外科展望

近年来,恶性肿瘤寡转移或寡进展状态逐渐成为癌症领域的研究热点。因其相对惰性的肿瘤生物学特征,以及潜在的局部治疗获益机会,寡转移或寡进展在多个癌种中被列为特殊的临床亚型,然而在食管鳞状细胞癌中尚无深入的研究。食管鳞状细胞癌是否存在寡转移状态,孤立性区域淋巴结转移是否应视为食管鳞状细胞癌术后寡进展,外科治疗在寡转移中的临床价值,以及局部放疗在寡进展中的临床价值,文献报道了一些有价值的成果,但仍需进一步探索。谨慎推进相关研究,明确食管鳞状细胞癌寡转移或寡进展的生物学特点和预后特征,有望为患者制定效果更佳的个性化治疗方案。